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Abstract 
Background 
The human neuroblastoma cell line, SH-SY5Y, is a commonly used cell line in studies 
related to neurotoxicity, oxidative stress, and neurodegenerative diseases. Although this cell 
line is often used as a cellular model for Parkinson’s disease, the relevance of this cellular 
model in the context of Parkinson’s disease (PD) and other neurodegenerative diseases has 
not yet been systematically evaluated. 
Results 
We have used a systems genomics approach to characterize the SH-SY5Y cell line using 
whole-genome sequencing to determine the genetic content of the cell line and used 
transcriptomics and proteomics data to determine molecular correlations. Further, we 
integrated genomic variants using a network analysis approach to evaluate the suitability of 
the SH-SY5Y cell line for perturbation experiments in the context of neurodegenerative 
diseases, including PD. 
Conclusions 
The systems genomics approach showed consistency across different biological levels (DNA, 
RNA and protein concentrations). Most of the genes belonging to the major Parkinson’s 
disease pathways and modules were intact in the SH-SY5Y genome. Specifically, each 
analysed gene related to PD has at least one intact copy in SH-SY5Y. The disease-specific 
network analysis approach ranked the genetic integrity of SH-SY5Y as higher for PD than for 
Alzheimer’s disease but lower than for Huntington’s disease and Amyotrophic Lateral 
Sclerosis for loss of function perturbation experiments. 
Keywords 
SH-SY5Y, Cell line, Whole genome sequencing, RNA-seq, Proteomics, Cell line suitability 
evaluation, Parkinson’s disease 
Background 
Cell lines are widely used for perturbation experiments that aim to understand disease 
mechanisms at a cellular level. Cells used in such experiments are only rarely an inherent 
biological model for the disease of interest. Most commonly, genetic or environmental 
perturbations are required to create cellular responses, which can then serve as an 
experimental disease model. It is known that many cell lines carry major genetic variations, 
which would be lethal for humans at the stage of prenatal development. The main advantage 
of highly proliferative cell lines relative to primary cells and induced pluripotent stem cells is 
a significantly greater capacity for experiments that require large amounts of clonal cells with 
identical genetic background, such as needed in state-of-the-art high-throughput screening, 
especially in proteomics or metabolomics. The availability of clonal cells allows the 
possibility for comparative perturbation experiments aiming to compare phenotypic outputs 
derived from a set of single node perturbations [1]. In addition, using cell lines avoids the 
ethical concerns arising out of human primary neuronal cell culture. The human 
neuroblastoma cell line SH-SY5Y first described in [2], is a commonly used cell line in 
studies related to neuroblastoma and neurodegenerative disease. The cell line is a sub-clone 
of the parent cell line SK-N-SH which was originally established from a bone marrow biopsy 
of a neuroblastoma patient [3]. The three human diseases most frequently mentioned in 
literature for SH-SY5Y were neuroblastoma, Alzheimer’s disease (AD), and Parkinson’s 
disease (PD) (Additional file 1). A complete genomic characterization of SH-SY5Y would 
thus elucidate the applicability and possible limits for modelling these disease-specific 
processes in the context of this cell line. 
Undifferentiated SH-SY5Y cells have been extensively used as an in vitro model for research 
in neuroscience [4]. The cell line shows biochemical properties of immature 
catecholaminergic neurons [2]. Studies have found that undifferentiated SH-SY5Y express 
only immature neuronal markers and lack mature neuronal markers [2,5]. Thus, 
undifferentiated SH-SY5Y cell line might not represent an appropriate model for diseases 
such as PD, which primarily affect differentiated dopaminergic neurons [6]. Further, Xie et 
al. [4] reviewed 60 articles on SH-SY5Y cell as in vitro model for PD research and found that 
differentiation of SH-SY5Y under a certain treatment results in a more dopaminergic 
neuronal phenotype, which could be extremely useful for modelling selective dopaminergic 
cell death in PD. However, they point out that an optimally differentiated SH-SY5Y 
dopaminergic cell model requires further research. A systems genomics analysis could 
thoroughly assess the genetic mutations in all neuronal markers and therefore place limits on 
how closely differentiation can model a dopaminergic cell. 
Furthermore, treatment with differentiation-inducing agents enable SH-SY5Y cells to become 
morphologically similar to mature primary neurons [7], and the different treatment agents 
(e.g. retinoic acid, phorbol esters, dibutryl cyclic adenosine monophosphate) result in a 
variety of neuronal phenotypes (e.g. cholinergic, dopaminergic, noradrenergic) [8]. Genomic 
mutations may, however, impose limitations on the possible phenotypes to which SH-SY5Y 
can differentiate. Therefore, a complete genomic characterisation of the SH-SY5Y cell line 
can inform the limitations on the possible phenotypes imposed by the genome. 
Systems genomics aims to integrate genomic variation, copy number and structural variation 
with high-throughput gene expression, metabolomics and proteomic data to explore the 
genetic architecture of complex traits and multi-factorial diseases. For characterizing the SH-
SY5Y cell line we integrated information from whole genome sequencing, transcriptomics, 
and proteomics experiments (Figure 1). Firstly, whole-genome sequencing is used to 
determine the genetic background of the cell line. Secondly, transcriptomics and proteomics 
data is used to study correlation across biological levels. Finally, we integrate genomic 
variants using a network analysis approach to evaluate the suitability of the SH-SY5Y cell 
line as an in vitro model to study various neurodegenerative diseases, including PD. 
Figure 1 Systems genomics approach to assess SH-SY5Y as a disease model. 
Results 
Whole genome sequencing 
The whole genome of SH-SY5Y cell line was re-sequenced using two different sequencing 
platforms, those from Complete Genomics (CG) and Illumina (IL) HiSeq2000, to generate a 
high-quality list of variants. An earlier study has shown the utility of combining information 
from both platforms and although they show high concordance, each platform alone failed to 
detect a significant number of exonic variants spread over 1,676 genes [9]. 
For the SH-SY5Y cell line, DNA sequencing by CG [10] and IL [11] produced a genome-
wide coverage of 57× and 49× respectively. (Additional file 2: Table S2) More than 90% of 
the genome was covered by a minimum read depth of 20 (Additional file 2: Figure S1 and 
S2). Further, more than 95% of the exome was called with minimum required confidence set 
by each of the proprietary genotype-calling procedures of the two respective sequencing 
platforms. The two genome-sequencing platforms – CG and IL – produced a total union of 
3,896,055 single nucleotide variations (SNVs) with 84% concordance between both 
platforms. Filtering them based on criteria defined in Reumers et al. [12] resulted in 
2,314,627 SNVs with 99% concordance between both platforms. Out of these high quality 
variants 96% were previously reported by dbSNP build 137 [13] and 98.4% by 1000 
Genomes Project [14,15]. 4,336 SNVs and small indels were earlier reported by the 
Catalogue of Somatic Mutations in Cancer (COSMIC) [16] version 64. The total number of 
SNVs and the percentage of SNVs found in 1000 Genomes Project are similar to controls 
(mean number of SNVs = 4,178,701 and 87.7% of them were found in 1000 Genomes 
Project, see Additional file 2: Table S7) in another study [17] taken from the Human Genome 
Diversity Project [18]. Among the high confidence set of mutations in SH-SY5Y, 23 were 
confirmed as somatic in the COSMIC database and were also rare in the general population 
(see Table 1). 
Table 1 High-confidence mutations in SH-SY5Y that were rare in the population and also confirmed as somatic in the COSMIC 
database 
Chromosome:begin-end COSMIC ID (tissue type) Genes (or adjacent genes) 
2:174118525-174118526 140009 (skin) MLK7-AS1 
3:3965330-3965331 146267 (haematopoietic_and_lymphoid_tissue) LRRN1(dist = 75944), SETMAR(dist = 379657) 
3:97631173-97631174 166940 (large_intestine) ARL6(dist = 113801), MINA(dist = 29487) 
3:97680355-97680356 166941 (large_intestine) MINA 
3:195017896-195017897 212624 (breast) ACAP2 
4:62000660-62000661 200267 (large_intestine) LOC255130 (dist = 3929195), LPHN3(dist = 362178) 
5:40086690-40086691 145684 (haematopoietic_and_lymphoid_tissue) DAB2(dist = 661356), PTGER4(dist = 593341) 
6:35837057-35837058 167752 (large_intestine) SRPK1 
6:152632032-152632033 167911 (large_intestine) SYNE1 
6:168431497-168431498 85018 (pancreas) KIF25 
7:127075991-127075992 200565 (large_intestine) ZNF800(dist = 43225), GCC1(dist = 144690) 
8:27913552-27913553 1098826, 1098827 (endometrium) C8orf80 
8:38006195-38006196 187133 (large_intestine) STAR 
9:6254465-6254466 1109518 (endometrium) IL33 
11:57734912-57734913 146001 (haematopoietic_and_lymphoid_tissue, large_intestine) TMX2-CTNND1(dist = 148261), OR9Q1(dist = 56440) 
12:7585976-7585977 179792 (large_intestine) CD163L1 
12:11905442-11905443 180918 (large_intestine) ETV6 
12:88344608-88344609 433706 (breast) MKRN9P(dist = 166121), C12orf50(dist = 29207) 
14:72128130-72128131 195414 (large_intestine) SIPA1L1 
16:12798881-12798882 1202185 (large_intestine) CPPED1 
19:11134250-11134251 1161250, 1161251 (haematopoietic_and_lymphoid_tissue) SMARCA4 
X:47039372-47039373 1121715 (endometrium) RBM10 
X:104440586-104440587 487453 (kidney) IL1RAPL2 
Rare mutations are SNVs and small indels that were found in less than 5% of the samples in 1000 Genomes Project, Exome Sequencing Project 
and Complete Genomics baseline genomes. In the genes column, when distances are given, the mutations are found in intergenic regions and the 
first gene precedes the mutation whereas the second gene succeeds the mutation. 
The number of private protein-altering (PPA) SNVs and indels, i.e. protein-altering variants 
not found in 1000 Genome Project or the Exome Sequencing Project [19] were 75 and 34 
respectively (1,598 SNVs and 305 indels before filtering), whereas the corresponding 
numbers for controls were 390.9 and 17.5. The set of control genomes refers to 11 genomes 
used in another study [17] taken from the Human Genome Diversity Project [18]. The reason 
for the discrepancy between the number of PPA SNVs between SH-SY5Y and the control 
genomes is mainly due to our strict filtering strategy as well as the different sequencing 
platforms that were used (See Additional file 2 – section S6 for further details). The overlap 
between PPA variants and the variants in the Catalogue of Somatic Mutations in Cancer 
(COSMIC) was 36 and 8.7 for SH-SY5Y and control genomes respectively. The overlap 
between genes containing PPA SNVs and indels and the Sanger Cancer Gene Census 
(SCGC) [16] was 7, similar to controls (mean n = 5). 
We also performed a Gene Ontology (GO) enrichment analysis on the 121 genes containing 
filtered PPA SNVs and indels and also on the 1,365 genes using unfiltered PPA SNVs and 
indels. However, no GO term was significantly enriched (see Additional file 3). 
We judged the overall quality of the variant calls and also compared them between the two 
genome sequencing platforms - CG and IL. Then, we integrated variant calls from both these 
platforms by using the filtering criteria provided by an earlier study [12] that compared these 
two platforms (See section S2 for an overview of the comparison between CG and IL 
sequencing platforms). 
Validation of SNVs and small indels 
Validation was performed using the Illumina Omni-1 Quad microarray, which assays loci 
from HapMap Phase 1–3 [20] and 1000 Genomes Project. Out of 248,538 heterogeneous 
SNVs that were queried by genotyping, 99.0% were concordant, which increased to 99.5% 
for the filtered variants (Additional file 2: Table S11). 
Functional prediction of SNVs and small indels 
The functional effect of SNVs and small indels were predicted using ANNOVAR [21] by 
annotation with labels for genomic regions (intergenic, exonic, intronic, un-translated 
regions, upstream and downstream close to a gene) and coding effects (SNVs - synonymous, 
missense, stop-gain, stop-loss - and indels - frameshift and non-frameshift). The annotation 
was performed by taking a consensus across four databases (RefSeq refgene release 55 [22], 
UCSC knowngene [23], Ensembl ensgene v65 [24] and GENCODE V4 [25]) based on 
choosing the most damaging effect predicted in order to aim for sensitivity (Additional file 2: 
Figures S4–S9). In general, the association of SNVs to genomic regions for platform-specific 
and concordant SNVs did not show any significant differences. The association of SNVs with 
exonic, intronic and intergenic regions was 1%, 26–36% and 46–50% respectively, similar to 
the results in Lam et al. [9] (Additional file 2: Figure S4 and S5). The functional prediction 
found 366 genes with rare non-synonymous SNVs, indels or substitutions (<5% frequency in 
1000 Genome Project, 6500 Exome Sequencing Project and CG Baseline Genome Dataset). 
Neuroblastoma-relevant genes 
The genome sequencing of SH-SY5Y found 27 genes with rare non-synonymous SNVs, 
indels or substitutions that overlapped with the list of 586 genes containing somatic mutations 
in the complete genome sequence of 87 untreated primary neuroblastoma tumours [26] (See 
Additional file 2: Table S12). Using the hyper-geometric test, genes with rare non-
synonymous SNVs and indels were found to be significantly enriched among the genes with 
somatic mutations in primary neuroblastoma tumours (p-value = 6.80 × 10−13). Out of these 
27 genes, only mutations in 15 genes were predicted as damaging by Sorting Intolerant From 
Tolerant (SIFT) [27]. 
Furthermore, only 3 genes with rare non-synonymous SNVs, indels and substitutions 
overlapped with the 118 genes associated with neuroblastoma in the literature (see Methods 
section) and therefore were not significantly enriched (p-value = 0.072). However, genes with 
non-synonymous SNVs, indels and substitutions, copy number variations, and structural 
variations (n = 3611) were significantly enriched among the 118 genes extracted for 
neuroblastoma from literature with an overlap of 28 genes (p-value = 1.59 × 10−7). 
We also compared genomic mutations in SH-SY5Y to other genomic sequencing studies of 
primary neuroblastoma from patients. Among the seven genes mutated at a significant 
frequency in a study of 240 matched tumour -normal samples [28], none of the genes carried 
a rare amino-acid changing mutation. Among the rare germ-line variants predisposing to 
neuroblastoma identified by the TARGET study, PALB2 contained two rare non-synonymous 
mutations in SH-SY5Y. Among the 5,291 coding somatic mutations found in an aggregate of 
240 matched tumour/normal samples, we found 26 overlapping variants (Additional file 3) in 
SH-SY5Y inside 24 genes among which 9 were rare amino-acid changing mutations inside 7 
genes (ALK, FOXD4L1, HLA-DRB1, NBPF10, NBPF14, PABPC3, TEKT4). 
The Pediatric Cancer Genome Project (PCGP) conducted a study of 40 patients with 
metastatic neuroblastoma and found mutations in ATRX and ALK in 22% and 14% of the 
patients correspondingly [29]. However, SH-SY5Y contained no rare amino-acid-changing 
mutations in these genes. 
Structural Variations (SV) and Mobile Element Insertions (MEI) 
Structural variation events consist of large deletions (>200 base-pairs), duplications (distal or 
tandem), inversions, translocations and complex variations - other combinations of such 
chromosomal rearrangements. The majority of SV events in the SH-SY5Y cell line found by 
CG were deletions (Additional file 2: Table S12 and S13). 
Around 2–3% of cancers show chromothripsis [30], where tens to hundreds of genomic 
rearrangements occur in a cellular crisis event. In a certain region, a high density of genomic 
rearrangements (or breakpoints) combined with frequent oscillations between two copy 
number states [30] and frequent occurrences of runs of homozygosity constitute the hallmark 
of chromothripsis. Cytogenetic methods confirm a high density of genomic breakpoints in 
single cells and indicate that these breakpoints are not a result of parallel rearrangements in 
different sub-clones [30]. 
However, for SH-SY5Y, DNA sequencing found little to no evidence of chromothripsis. 
Most notably, no oscillations between copy number states of 100-kb binned read depth were 
observed except for some on chromosomes 9, 10, 16 and X (Additional file 4). In all of these 
four chromosomes, the regions with oscillating copy number were near the centromeres (9, 
10, 16) or the telomere (16, X). Even though all of these regions have at least six junctions, 
these regions consist of highly repetitive DNA [31] and are therefore prone to mapping 
errors. 
We filtered the SVs based on their frequency in the CG baseline genome set [32] and 
extracted high-confidence calls with a frequency of less than 10% in the baseline. The CG 
baseline set comprises of 52 genomes of healthy, disease-free individuals, which could be 
used to filter technical artifacts and variations common in the population. After filtering, the 
high-confidence deletions overlapped with 26 genes including the following cancer-related 
genes - PTEN (phosphatase and tensin homolog), which is a key tumour suppressor gene 
[33], CTNNA3 (catenin alpha 3), which is a cell contact inhibition gene whose mutation can 
promote cancer development and formation, MCC (mutated in colorectal cancers) and 
MTUS1 (microtubule associated tumour suppressor 1). 
Mobile element insertions (MEI) refer to insertion of sequences that can change their position 
within the genome. 3,271 MEI events were detected in the CG data (Additional file 2: Table 
S14) and the majority of those were Alu events (n = 2,057) and L1 retro-transposons (n = 
2,057). 
Copy number variation (CNV) 
CG identifies discrete coverage levels corresponding to ploidy levels using the distribution of 
observed normalized coverage values and then uses a hidden Markov model to assign copy 
number levels (Complete Genomics Data File Formats Standard Pipeline 2.4 [34]). Since CG 
essentially uses the relative coverage as a proxy for copy number, it cannot directly infer the 
absolute copy number levels. However, M-FISH (multiplexed fluorescent in-situ 
hybridization) experiments have demonstrated that diploidy dominates the copy number level 
in the SH-SY5Y genome [35]. Therefore, we calculated the absolute copy number levels 
assuming that the most commonly found copy number level is 2. 
We compared the copy number levels found by CG with an earlier measurement using 
comparative genomic hybridization (CGH) arrays [36]. The CGH arrays used had a lower 
limit one million base pairs to their resolution, a drawback not found in second-generation 
sequencing technologies such as CG and IL. To achieve even higher resolutions and reduce 
false positive and false negative copy number determinations, we normalized the coverage 
levels to those observed in a reference set of 590 in-house genomes also sequenced by CG. A 
visual illustration of the copy number levels (Figure 2, Additional file 2: Figure S21) 
confirms key features of the cell line described previously such as partial trisomy of 
chromosome 1, gain of chromosome 7, 2p, 17q, and loss of 1p, 14q and 22q. Among the 
large-scale copy number features identified in the PCGP project, the gain of 17q (90%) was 
common with SH-SY5Y. The remaining CNVs that were reported with a lower frequency in 
PCGP - loss of 1p (43%) or loss of 11q (43%) were not found in SH-SY5Y. 
Figure 2 CNVs detected by whole genome sequencing and array-based CGH by Do et 
al. [36]. The results from whole genome sequencing were from Complete Genomics and are 
given in the left half of the chromosomes. The results from the array-based CGH are on the 
right half of the chromosomes. Regions are highlighted for copy number gain (red) and loss 
(blue). The major events partial trisomy of chromosome 1 and 2, complete trisomy of 
chromosome 7, gain in 17q and loss in 22q were confirmed. (Generated using 
http://db.systemsbiology.net/gestalt/cgi-pub/genomeMapBlocks.pl). 
Interestingly, the strongest clinical marker of neuroblastoma that also determines the 
aggressiveness of neuroblastoma [36] - gain of the gene MYCN (myelocytomatosis viral-
related) – actually had a relative coverage of only 3. However, more recently, [35] confirmed 
the finding that the MYCN gene is not strongly amplified in SH-SY5Y. Also, among the 104 
patients sequenced in the PCGP project, only 23% carried an amplification of MYCN, which 
was defined as >10 copies detect by quantitative-PCR. 
Transcriptome analysis 
To characterize the SH-SY5Y cell line gene expression, we sequenced poly-adenylated RNA 
from undifferentiated SH-SY5Y cells using a stranded RNA-seq protocol. We used the 
GRCh37 human genome version together with the Ensembl release 66 [24] gene annotation. 
We generated about 100 million paired-end reads of lengths 50 nt. The raw reads are 
available in the European Nucleotide Archive (ENA) database [37] under the study accession 
PRJEB7313. In total, 94 million paired-end reads and 4.6 million singleton reads could be 
mapped after quality control (QC) filtering and trimming to either the genome or the 
transcriptome annotation. This yields in 95% mappable reads to either genome or cDNA 
sequences. 
For RNA-seq, we called SNVs and small indels using both SAMTools [38] and the Genome 
Analysis Toolkit (GATK) [39]. We retained the intersection of the two outputs and those 
caller-specific variants supported with a read depth greater than or equal to 10. As a recent 
study has shown low concordance between multiple variant-calling pipelines [40], we 
decided to increase the level of confidence by using two variant-calling pipelines. 
Consequently for RNA-seq, out of 95,173 SNVs and small indels detected, 70.2% were 
concordant with unfiltered variants from at least one DNA sequencing platform, either CG or 
IL (Additional file 2: Table S17). The RNA-seq also showed high sensitivity as 95.1% of the 
3,500 filtered exonic variants found through DNA sequencing in genes with FPKM > 5 were 
also detected by RNA-seq. FPKM refers to Fragments Per Kilobase of exon per Million 
fragments mapped, which is a measure of gene expression. This sensitivity of RNA-seq for 
variant detection was higher than that achieved by a recent approach for SNV calling in 
RNA-seq data [41] but the absolute number of detected exonic variants (n = 3,300) was 
slightly lower than theirs (n = 4,000), which might be due to our strict quality filtering of the 
DNA sequencing data. As for neuroblastoma-relevant genes from the 87 neuroblastoma 
primary tumours, out of the 30 rare, amino-acid changing mutations (in 27 genes), 10 of them 
were detected by RNA-seq with the same zygosity. The remaining 20 were likely not 
detected because of low gene expression as all mutations detected by RNA-seq were in genes 
with FPKM > 3.1 and all mutations not found by RNA-seq were in genes with FPKM < 0.57. 
Genetic copy number vs. gene expression 
We compared genes that were always expressed in SH-SY5Y across 247 different conditions 
(Additional file 5) from the GEO (Gene Expression Omnibus) database [42] to those that 
were never expressed, whenever the corresponding probe was present. Here, the threshold 
used to determine whether genes were always expressed in the GEO dataset was that the 
expression values of the corresponding transcripts were always greater than the median for all 
the transcripts in each microarray experiment. Similarly, the threshold for genes never 
expressed in the GEO dataset was that the expression values were always less than the 
median for all the transcripts in each microarray experiment. The frequency of mutations per 
100 kilo-base-pair region in genes that were never expressed was 165.36, which decreased to 
131.31 for genes, which were always expressed. Similarly, the average copy number for 
genes always expressed was 2.18, which was lowered to 2.09 for genes never expressed 
(Additional file 2: Table S22). The distribution of expression of genes with copy number 
greater than 2 was significantly greater (Welch’s t-test p-value = 2.2 × 10−16) than expression 
of genes with copy number lower than or equal to 2 (Additional file 2 – section S27). 
Further, we compared the genetic copy number and the RNA-Seq data of the same SH-SY5Y 
sample. The copy number and the logarithm of Fragments per kilo-base of transcripts per 
million mapped reads (FPKM) showed a positive correlation (Additional file 2: Figure S24). 
Proteome analysis 
In order to confirm and correlate the biological expression of the identified genes, the 
analysis of genomic data was integrated with the analysis of proteomics data analysis of SH-
SY5Y cell lysates (see Methods section for complete details). Proteins isolated from whole 
SH-SY5Y cell lysates were fractionated by SDS-PAGE, in-gel digested using trypsin, and the 
recovered peptides analysed by LC-ESI MS/MS. The spectra were analysed by MaxQuant 
against a combinatorial human protein database. This database contained the human genome 
reference hg19 protein entries combined with the sequence variants found from the DNA 
sequencing done here. Specifically, the coding sequences of Ensembl genes were modified 
using all the homozygous exonic variants (unfiltered). 
In total, out of 334,065 acquired MS/MS spectra, 165,494 were matched to a peptide that 
could be mapped to a total of 1,410 protein identifiers (Additional file 2: Table S21). From 
these, 1,944 protein groups corresponding to 1,355 proteins were identified in the human 
genome reference hg19 protein annotation. Further, 45 proteins were identified using 
sequence variants found from the DNA sequencing done here. See Additional file 6 for the 
abundances of proteins detected. 
To increase peptide spectrum matches, we extended the human genome reference hg19 
protein database by inserting reference sequences containing the homozygous SNVs and 
indels in the exonic regions identified in this study. The peptides that were additionally 
mapped to the extended protein database were then used for validation of genetic variants 
(Additional file 2 – section S24). This approach validated 104 SNVs, 4 indels and 1 block 
substitution. 
Gene expression vs. protein expression 
Gene expression levels from RNA-seq and the corresponding protein abundance were 
compared to detect correlation. We plotted the logarithm of FPKM against the logarithm of 
intensity–based absolute quantification (iBAQ) [43] score of 1,307 genes (Additional file 2: 
Figure S25 and Table S25), which were detected in both RNA-seq and proteomics, which 
equals 93% of 1,410 proteins detected by proteomics. As expected, the correlation was 
weakly positive (correlation coefficient = 0.2784, p = 10−27, see Additional file 2: Figure 
S26). 
Network-based analysis of suitability of SH-SY5Y cell line as in vitro model 
In order to evaluate the suitability of SH-SY5Y as in vitro model we adopted a framework 
described in [44] that integrated genetic sequence information, and topology analysis of 
either disease or process-specific networks. We applied betweenness-centrality ratio (BC-
ratio), a metric that allowed us to quantitatively assess the impact of genes mutated in the cell 
line on the disease or process network. BC-ratio is normalized to lie between 0.0 and 1.0. It 
indicates how much the information flow in the network might be altered by changes in the 
cell line: the higher BC-ratio, the greater the impact of the mutations, the lower the genetic 
integrity (or suitability) of the cell line in the context of a specific network. (See Methods 
section for a detailed discussion of the approach). The BC-ratio metric applied to four 
neurodegenerative diseases (Table 2) ranked Alzheimer’s (AD) as highest BC-ratio = 0.246 , 
pBC-value = 0.04), followed by Parkinson’s disease (BC-ratio = 0.186, pBC-value 0.168), 
Huntington disease (BC-ratio = 0.146, pBC value = 0.472), and Amyothrophic Lateral 
Sclerosis (BC-ratio = 0.084, pBC-value = 0.922 ). To investigate the appropriateness of the 
cell line for perturbation experiments in the context of PD, we also scored the different 
processes corresponding to the hallmarks of PD (Table 3). See Figure 3 for a protein-protein 
interaction network resulting in the cell line suitability scores for neuroblastoma and ALS and 
Figure 4 for the network for glycolysis and reactive oxygen species (ROS) metabolism in PD. 
Additional file 7 contains network visualizations for each disease and each module in PD. 
The role of the visualization is to give an idea of how damaged genes are distributed in the 
network, to which genes they are connected and how they could alter processes of interest. 
Table 2 Network statistics and cell line scoring of the neurodegenrative diseases and 
neuroblastoma 
Disease 
Name 
Nodes Edges Network 
Centralization 
(Betweenness) 
Cell Line Suitability based on 
Centrality Metrics 
pBC-
value 
Total Damaged Intact Degree Closeness BC-
ratio 
Flow 
BC 
NB 63 15 48 192 .650 .362 .248 .591 .430 .010 
AD 248 40 208 929 .405 .208 .161 .246 .215* .040 
PD 358 55 33 1862 .246 .156 .153 .186 .176* .168 
HD 63 10 53 153 .624 .183 .163 .146 .162 .472 
ALS 178 22 156 371 .399 .116 .171 .084 .126* .922 
Flow BC stands for flow betweenness centrality. The PBC-value refers to the network 
randomization test described in the Methods section. Flow Betwenness is defined for 
connected networks. If the entire network is not connected, Flow betweenness is computed 
for connected components. In the table the flow betweenness centrality of the largest 
connected component is given and marked by *. NB – Neuroblastoma; AD – Alzheimer’s 
disease; PD – Parkinson’s disease; HD – Huntington’s disease; ALS – Amyotrophic Lateral 
Sclerosis. 
  
Table 3 Network statistics and cell line scoring of the Parkinson’s disease modules 
Module Name Nodes Edges Network centra-
lization (Bet-
weeness) 
Cell Line Suitability based on 
Centrality Metrics 
pBC-
value 
Total Damaged Intact Degree Closeness BC-
ratio 
Flow 
BC 
Glycolysis 23 6 17 59 .321 .262 .256 .310 .253 .330 
Mitochondria 259 32 227 4752 .127 .135 .137 .155 .128* .297 
Calcium Signalling 125 17 108 561 .160 .163 .132 .149 .095* .296 
Apoptosis 122 15 107 250 .334 .080 .117 .146 .098* .279 
Dopamine 54 8 46 175 .030 .174 .179 .115 .224* .448 
Ubiquitin Protease System 55 7 48 809 .070 .150 .153 .044 .133* .340 
ROS metabolism 58 3 55 121 .922 .012 .051 .000 .000 .375 
Flow BC stands for flow betweenness centrality.The PBC-value refers to the network 
randomization test described in the Methods section. Flow Betwenness is defined for 
connected networks. If the entire network is not connected, Flow betweenness is computed 
for connected components. In the table the flow betweenness centrality value of the largest 
connected component is given and marked by *. 
Figure 3 Protein-protein interaction network for two diseases – neuroblastoma (A) and 
for ALS (B). Red nodes refer to OMIM-derived genes mutated in the cell line. Orange nodes 
refer to the OMIM-derived genes which are intact in the cell line. Dark green nodes represent 
genes coming from the network expansion, which are mutated in the cell line. Light green 
nodes represent genes coming from the network expansion, which are intact in the cell line. 
Nodes are scaled to the magnitude of their betweenness centralities. Blue edges show 
connections between pairs of nodes in which at least one was damaged in the cell line. For 
neuroblastoma, mutations in the central genes – NME1 and ALK contribute to the high BC-
ratio. For the ALS network, mutations occur in genes with lower betweenness centrality 
which results in the lower BC-ratio. 
Figure 4 Protein-protein interaction network for two PD map modules - glycolysis (A) 
and ROS metabolism (B). Red nodes refer to genes mutated in the cell line. Orange nodes 
refer to genes which are intact in the cell line. Nodes are scaled to the magnitude of their 
betweenness centralities. Blue edges show connections between pairs of nodes in which at 
least one was damaged in the cell line. For glycolysis, mutations in the central genes lead to 
the high BC-ratio. Mutated genes lie on the periphery of the ROS metabolism network 
resulting in a low BC-ratio. 
Discussion 
The complete system-wide omics analysis of the undifferentiated SH-SY5Y cell line 
provided many opportunities for studying concordance across biological levels (DNA, RNA, 
protein). Firstly, protein-altering variants, copy number variations and structural variations 
show consistency with the expression level of genes in the RNA-seq data. For instance, 
variant calling from RNA-seq data showed 95.1% sensitivity for the 3,500 filtered variants 
detected from DNA-seq in genes with an FPKM > 5. Secondly, sequencing both the DNA 
and the RNA showed a high degree of concordant SNVs and indels (95.1% for genes with 
FPKM > 5 were detected by RNA-seq) and served as further validation of DNA sequencing 
results and our filtering procedure for genomic variants. Finally, the knowledge of genomic 
variants enhanced protein identification in proteomics experiments where it increased the 
number of proteins detected from 1,365 to 1,410. 
A comparison of the two whole genome sequencing platforms – Complete Genomics (CG) 
and Illumina (IL) – confirmed a significant number of variants that were discordant, either 
due to regions, which were not called by one of the platforms or due to platform-specific 
errors. Considering that 1% (n = 4,321) of these platform-specific variants residing in 2,348 
genes were associated with exonic regions, using both platforms would increase the detection 
of potentially functionally important SNVs. Also only 75–80% of platform-specific variants 
were found in the known list of variants (in dbSNP, 1000 Genomes Project or 6500 Exome 
Sequencing Project), indicating that a significant number of mutations are somatic mutations 
or sequencing errors that need further investigation. Further, the larger platform-specific 
biases for small indels and structural variations also strengthened the argument for using both 
platforms for greater sequencing accuracy. 
Neuroblastoma-relevant genetic variations 
Without the genome sequence of the healthy cells from the patient, the difficulty of 
identifying somatic mutations in SH-SY5Y precludes any direct comparison to the somatic 
mutations in primary neuroblastoma tumours. Thus, we compared rare mutations in SH-
SY5Y with the somatic mutations found in 87 primary neuroblastoma tumours. The union of 
genes from 87 different patient samples resulted in a list of 586 genes, which we considered 
as relevant to neuroblastoma. The result that only 15 genes with rare amino-acid changing 
mutations predicted as damaging in SH-SY5Y overlapped with the list of 586 genes with 
somatic amino-acid changing mutations in primary neuroblastoma was expected as there was 
considerable heterogeneity among the different tumour samples themselves. Specifically, the 
sequencing of 87 neuroblastoma primary tumours found few recurrent genes with amino-acid 
changing mutations - only 24 genes contained amino-acid changing mutations in more than 1 
tumour sample and only three genes in more than two tumour samples. In this context, an 
overlap of 15 genes with rare amino-acid changing mutations suggests that SH-SY5Y 
includes elements of the genetic architecture of a variety of neuroblastoma tumours. 
Therefore, it might offer opportunities to investigate traits arising from amino-acid changing 
mutations found in different kinds of neuroblastoma tumours. 
As for structural variations, recurrently occurring structural alterations in the neuroblastoma 
primary tumours in PTPRD, ODZ3 and CSMD1 were not found among high-confidence rare 
structural alterations in SH-SY5Y. Finally, chromothripsis, which was earlier identified in 
18% of primary neuroblastoma, was not detected in SH-SY5Y. Therefore, SH-SY5Y would 
not serve as an appropriate model for neuroblastoma tumours suffering from chromothripsis. 
Suitability of SH-SY5Y as an in vitro model for neurodegenerative diseases 
The BC-ratio relies on the network betweennness centrality to quantify genetic changes in the 
cell line. It is important to consider that the BC-ratio does not aim to interpret the functional 
effects of these mutations. Indeed, mutations could cause a loss, gain, change or no change in 
the function. However, such interpretations require assumptions. In the case of 
neuroblastoma, we know that the SH-SY5Y cell line was derived from a neuroblastoma 
patient. Hence, it can be assumed that many genetic mutations, which were observed in the 
neuroblastoma network (BC-ratio = 0.591, pBC-value 0.01), are indeed typical neuroblastoma 
mutations. Specifically, copy number variations in the central neuroblastoma genes NME1 
and ALK (Figure 3A), both of which are found to be mutated in neuroblastoma as well 
support this reasoning. Briefly, it can be assumed that SH-SY5Y cells are a good model for 
neuroblastoma cells and a high BC-ratio (Table 2) was expected. 
However, this case where a neuroblastoma cell line is expected to model neuroblastoma is a 
special case. This interpretation is similar to the approach of Domcke et al. [45] of choosing 
the ‘most suitable models’ for ovarian tumour among ovarian cancer cell lines based on 
genomic and mRNA expression profiles. Typically, in contrast, experimentalists use cell 
culture models to study processes lacking such ideal identity matching. Routinely, 
perturbation experiments are used to cause controllable genetic defects in networks, which 
are overall assumed to be intact [46]. However, potential genetic changes, which are ignored, 
can introduce errors into the interpretation of results. The main scope of the BC-ratio is to 
provide distances between networks of interest in a cell line and their ideal reference 
networks. A BC-ratio of 0.0 indicates an unchanged network representing an ideal reference 
for perturbation experiments. The pBC value evaluates if a BC-ratio > 0.0 was due to chance 
or it resulted from strong correlation between the nodes with high betweenness centrality and 
genes mutated in the cell line. Note that a non-significant pBC-value does not exclude any 
functional effects of network changes and it is strongly recommended to collect additional 
information for evaluating potential functional effects. While our aim was not to predict 
functional effects related to RNA or protein abundance, we are convinced that the provided 
data will support case-specific interpretations of functional network integrity. 
A central question of our investigation was whether context (i.e. disease or process)-specific 
networks are overall changed in SH-SY5Y. The absence of network changes was considered 
as ideal case for controllable perturbation experiments. In the following paragraphs, we first 
discuss the integrity of disease-specific networks in SH-SY5Y and secondly, focus on PD in 
more detail. 
The cell line suitability (BC-ratio) metric applied to four neurodegenerative diseases ranked 
them from those with the largest to the smallest changes in the network. Alzheimer’s disease 
(AD) was ranked as the highest, followed by Parkinson’s disease (PD), Huntington’s disease 
(HD) and, finally, Amyotrophic Lateral Sclerosis (ALS). BC-ratios in combination with the 
pBC-values tell us that genes mutated in the cell line are more likely to be involved in the 
information flow control in AD (pBC < 0.05) network than the same type of genes is in the 
networks of other diseases . Overall, except for the neuroblastoma, BC-ratios were rather low 
(max BC-ratio = 0.246), and pBC-values were not significant for all but neuroblastoma and 
Alzheimer’s disease. These results indicate that the networks related to PD, HD and ALS are 
largely intact in the SH-SY5Y cell line and the latter can be considered a suitable model for 
perturbation experiments targeting these diseases, while AD might require a special caution. 
It is also important to bear in mind that none of these disease-specific networks were 
perfectly intact. Indeed, the BC-ratio for each network was computed as greater than 0.0, 
which indicates that changes in these networks were detected. A prediction of potential 
functional effects of these network changes, including a classification in gain or loss of 
function goes beyond the scope of the BC-ratio but the provided data on RNA and protein 
abundances can support such interpretations. 
Genes from which the networks for the neurodegenerative diseases and neuroblastoma have 
been grown, were derived from the OMIM databse where they have been classified as having 
disease causative effect (See Methods for the details). We also calculated the BC-ratios of the 
respective networks assuming that only these seed genes have had been damaged in the cell 
line. In all cases the number of mutated genes decreased while the BC-ratios of the cell lines 
increased for all but neuroblastoma (Table 4). Note that in the case of neuroblastoma, the 
main actors which contributed to the high BC-ratio computed on the real data, already were 
OMIM genes, damaged in the cell line. Therefore a lower BC-ratio for neuroblastoma was 
expected in the absence of any other damaged genes. The BC-ratio of the Huntington’s 
disease increased considerably. This is mostly due to the gene HTT followed by PRNP, which 
have the highest betweenness centrality in the HD network. Alzheimer’s disease scores next 
with APP gene making the main contribution to the magnitude of the BC-ratio, being the first 
on the list of all genes. It is immediately followed by 6 more OMIM-derived genes while 
their betweenness centrality is more than two times smaller. Similar effect can be observed in 
the case of Amyotrophic Lateral Sclerosis: SOD1 has the highest betweenness centrality, 
followed by VCP and DCTN1 with almost twice as much lower betweenness. In this 
experiment, Parkinson’s disease had the lowest BC-ratio although the list was dominated by 5 
OMIM-derived genes. The explanation might lie in the low betweenness centralization of the 
network (Table 2). Network centralization [47] reflects how much variation is there in the 
centrality scores (in our case, betweenness centrality) among the nodes. The value of 0.246 
indicates that the scores are rather equally distributed among the nodes and there are no nodes 
with apparent brokering role. Therefore changing the node labels from intact to damaged in 
such network produces smaller effect than in the remaining diseases. 
Table 4 BC-ratios of the neurodegenerative diseases and neurobalstoma computed 
under assumption, that only OMIM-derived seed genes have been mutated. 
Disease Name Nodes Mutated (OMIM genes) Intact BC-ratio pBC-value 
Huntington’s Disease 63 2 61 0.536 <0.001 
Alzheimer’s Disease 248 13 235 0.495 < 0.001 
Neuroblastoma 63 3 60 0.480 0.002 
Amyotrophic Lateral Sclerosis 178 17 161 0.409 < 0.001 
Parkinsons’s Disease 358 15 343 0.379 < 0.001 
The increase in the BC-ratios of all neurodegenerative diseases with the causative OMIM 
genes being considered as damaged, suggests that the genes which indeed are mutated in the 
cell line have smaller positional advantages than OMIM genes in the corresponding networks 
and therefore might less be involved in the information flow control. We believe that this 
observation supports our conclusion about the overall SH-SY5Y cell line suitability for the 
experimental studies of the neurodegenerative diseases. 
To further analyse the suitability of the cell line as an in vitro model for PD, we studied the 
integrity of disease related sub-networks including mitochondrial dysfunction, reactive 
oxygen species (ROS) accumulation and calcium homeostasis [48]. Fujita et al. [48] recently 
provided a comprehensive PD map, which integrates metabolic reactions, gene regulation and 
signalling processes in this complex network. The network consists of sub-networks (also 
referred to as modules), which correspond to pathways and processes. In these networks, 
nodes represent genes, proteins or small molecules, and edges represent molecular 
interactions. 
We selected seven modules corresponding to hallmarks of PD [49] from the PD map and 
scored them according to the BC-ratio metric. The idea was to segregate PD-related modules 
as more suitable for studying gain or loss of function of a module. In descending order of BC-
ratio, the modules were glycolysis, mitochondria, calcium signalling, apoptosis, dopamine 
metabolism, ubiquitin proteasome system and reactive oxygen species (ROS) metabolism 
(Table 3). The PBC values indicated no significant changes in these networks. However, we 
found that the glycolysis module (Figure 4A) is the most impacted (BC-ratio = 0.31), which 
suggests that information flow through this module could be significantly altered by the 
genetic background of SH-SY5Y. One explanation for glycolysis being highly impacted 
could come from the fact that SH-SY5Y is a cancer cell line. It has been shown that 
glycolytic rates are higher in cancer cells than healthy ones [50,51], known as the Warburg 
effect [51], which has been suggested to confer a proliferative advantage to tumour cells. 
Conversely, the ROS metabolism module (Figure 4B) was the least impacted (BC-ratio = 
0.0), which would indicate that the genes, mutated in the cell line do not compromise the 
information flow in this network. 
For the functional interpretation beyond the BC-ratio, it is important to consider that most of 
the genetic variations found in the PD modules do not carry mutations, but almost exclusively 
copy number gains. Indeed, this gain of copy numbers is expected because of the partial 
trisomy of chromosomes 1, 2, and 17 and the full trisomy of chromosome 3. However, 
variations that alter the protein sequence occur in very few genes. Among all the damaged 
genes found in the seven modules from the PD-map, only four contained non-synonymous 
SNVs. The Sorting Intolerant From Tolerant (SIFT) [52] tool predicted only 3 (MYO6, 
HADH and GZMB) as damaging (SIFT score < 0.05). The gene MYO6, found in the calcium 
signalling module and involved in intracellular vesicle transport, contains a heterozygous 
non-synonymous mutation with a SIFT score of 0.01. It also plays an important role in 
trafficking and activity-dependent recruitment of AMPA receptors to synapses [53]. The gene 
HADH, found in the mitochondria module and which catalyses several reactions in beta-
oxidation, also contains a heterozygous non-synonymous mutation with a SIFT score of 0. 
The gene GZMB, found in the apoptosis module and which codes for a serine protease that is 
used by activated cytotoxic T lymphocytes to induce cell apoptosis [54], contains a rare non-
synonymous SNV with a SIFT score of 0.01. However, in each of these three genes, only one 
copy of the gene contains such rare non-synonymous mutations. Further, four genes 
(NDUFA6, TOMM22, ATP5L2) in the mitochondria module and one gene (XRCC6) in the 
apoptosis module had a copy number of one, leaving only a single working copy. NDUFA6 
has been shown to have a high degree of nitration and be associated with the oxidative 
damage to mitochondrial complex I [55]. TOMM22 plays an important role in mitochondrial 
clearance controlled by PINK1 –PARK2 pathways [56]. ATP5L2 is involved in hydrogen ion 
trans-membrane transport activity [57]. XRCC6 codes for the Ku70 protein, which repairs 
double bond breakage of DNA through the non-homologous end-joining pathway. Therefore, 
one should consider the damage to these genes when designing loss of function perturbation 
experiments. Indeed, it is important to test if the mutations per se cause a loss of function and 
to keep in mind that a function which is already lost cannot be lost a second time. Except for 
the 7 genes discussed above, all the genes in the modules of the PD map were free of 
translated mutations in SH-SY5Y. 
Genes related to dopamine metabolism in SH-SY5Y 
In summary, all the genes involved in the dopamine metabolism pathway (Figure 5) except 
CYP2D6, ADH1B and UGT1A10 were expressed with or without specific treatments. Further, 
CYP2D6, which contributes to dopamine biosynthesis through an alternative cytochrome 
P450-mediated pathway shown to exist in rats [58,59], has a copy number of one, which may 
contribute to the lower expression. Among the genes in the dopamine metabolism pathway 
that were expressed with or without specific treatments, only ADH1C and DBH contained a 
rare protein-altering mutation and DDC and AKR1B1 had a copy number of three. Only the 
mutation in ADH1C was predicted as damaging by SIFT. Therefore, the large majority of 
genes involved in dopamine metabolism contains no genetic damage and can be expressed 
under certain treatments. 
Figure 5 Dopamine biosynthesis and degradation and the genes coding key enzymes. 
This metabolic pathway is a modified version of a figure from Meiser et al. [60]. In addition 
to the enzymes involved, the genes coding for those enzymes have been added using the 
HumanCyc [61]. The mutations in SH-SY5Y affecting enzyme-encoding genes have been 
annotated only if they were rare protein-altering SNVs or indels, CNVs, or SVs. 
Conclusions 
In summary, we provide here the first whole genome analysis of the SH-SY5Y cell line, 
which is widely used as a model for various neurological diseases. We characterise the 
different types of biological information of SH-SY5Y – genomics, transcriptomics and 
proteomics - and compare the relationships between them in terms of expression levels and 
variants. The data related to the genome sequencing, RNA sequencing and proteomics can be 
found at the following URL - http://systemsbiology.uni.lu/shsy5y. Additionally, we also 
compare the SH-SY5Y genome using two widely used whole genome sequencing platforms 
and show that using the two platform-specific coverages and sensitivities to different indel 
sizes supplements each other. Finally, our analysis based on context-specific network 
integrity ranked the integrity of SH-SY5Y for Parkinson’s disease as higher than for 
Alzheimer’s disease but lower than for Amyotrophic Lateral Sclerosis and Huntington’s 
disease. In the context of different PD related sub-systems, the same approach ranked ROS 
metabolism as the most intact followed by the ubiquitin proteasome system, dopamine 
metabolism, calcium signalling, mitochondria and glycolysis. Overall, most of the genes 
belonging to the major Parkinson’s disease pathways and modules were intact in the SH-
SY5Y genome. Particularly, each analysed gene related to PD has at least one intact copy in 
SH-SY5Y. Therefore, somatic mutations do not significantly alter PD-related pathways in 
SH-SY5Y. Importantly, the systems genomics analysis was performed on the undifferentiated 
cell line although differentiated cell lines are considered better suited as in vitro models for 
PD. Our novel BC-ratio method for cell line scoring integrates a genomic characterisation of 
the cell line, core set of disease or process-related genes and a protein-protein interaction 
network. This method is not restricted to a specific cell line or disease and can be broadly 
applied. Furthermore, if multiple sequenced cell lines are available, the BC-ratio scores can 
also be used as a guide to select the cell line best suited for studying a particular disease. 
Methods 
SH-SY5Y cell culture 
SH-SY5Y cells were cultured from a passage 23 (P23) vial, purchased directly from ATCC 
(CRL-2266) (Figure 3). In the first step the cells were amplified during 4 passages for 
preparing passage 27 (P27) freezing stocks. The cells were furthermore amplified during 5 
passages for preparing passage 33 (P33) samples for omics analysis. DNA was extracted with 
the High Pure PCR Template Preparation Kit (Cat. #11796828001, Roche). The samples 
sequenced by Complete Genomics and Illumina platforms were of equal passage and derived 
from the same frozen cell stock. For RNA analysis the cells were lysed in Qiazol buffer and 
were frozen at −80°C. RNA extraction was performed using the miRNeasy Kit (Qiagen). For 
protein analysis the cells were washed two times with DPBS and for inhibition of proteases 
the cells were covered with complete (Roche) solution in ddH2O and were frozen at −80°C. 
DNA-Seq library preparation 
Identical passage samples were derived from the same freezing stock and have been 
sequenced by Complete Genomics and Illumina platforms. DNA extraction was performed 
on P33 cells using the High Pure PCR Template Preparation Kit (Cat. #11796828001, 
Roche). 1 µg of input DNA was sheared using the Covaris to an insert size of 100–900 bp. 
Sheared DNA was end-repaired by adding End Repair Mix (Illumina) and incubated at 30°C 
for 30 min. Following end-repair, AMPure XP Beads (Agencourt) were diluted with water 
and mixed with the DNA samples. The samples were incubated at room temperature for 15 
min then placed on a magnetic stand for 15 min. The supernatant was removed and discarded. 
The beads were washed with 80% ethanol twice, then allowed to air-dry for 15 min. The 
dried pellet was resuspended in Resuspension Buffer to elute the DNA. The 3′ ends were 
Adenylated by adding A-Tailing Mix (Illumina) and incubated at 37°C for 30 min. Ligation 
Mix and a barcoded DNA Adapter was added to each sample and incubated at 30°C for 10 
min. The reaction was stopped by adding Stop Ligation Buffer. The ligated DNA was cleaned 
up twice using undiluted AMPure XP Beads and eluted in Resuspension Buffer. PCR Primer 
Cocktail and PCR Master Mix were added to the ligated DNA and PCR was performed with 
the following settings: 98°C for 30 s incubation followed by 10 cycles of 98°C for 10 s, 60°C 
for 30 s, 72°C for 30 s, final incubation at 72°C for 5 min, hold at 10°C. The PCR reaction 
was cleaned up with AMPure XP Beads and the library was resuspended in Resuspension 
Buffer. 
The genomic DNA was sequenced by Illumina using the Illumina Fast Track Services (FTS) 
methodology: 
1. gDNA Quantitation. 
Genomic DNA is quantified prior to library construction using PicoGreen (Quant-iT™ 
PicoGreen dsDNA Reagent, Invitrogen, Catalog #: P11496). Quants are read with 
Spectromax Gemini XPS (Molecular Devices). 
2. Library Construction—PCR-Free. 
Paired-end libraries are manually generated from 500 ng–1ug of gDNA using the Illumina 
TruSeq DNA Sample Preparation Kit (Catalog #: FC-121-2001), based on the protocol in the 
TruSeq DNA PCR-Free Sample Preparation Guide. Pre-fragmentation gDNA cleanup is 
performed using paramagnetic sample purification beads (Agencourt AMPure XP reagents, 
Beckman Coulter). Samples are fragmented and libraries are size selected following 
fragmentation and end-repair using paramagnetic sample purification beads, targeting 300 bp 
inserts. Final libraries are quality controlled for size using a gel electrophoretic separation 
system and are quantified. 
3. Clustering and Sequencing—v3 Chemistry. 
Following library quantitation, DNA libraries are denatured, diluted, and clustered onto v3 
flow cells using the Illumina cBot™ system. cBot runs are performed based on the cBot User 
Guide, using the reagents provided in Illumina TruSeq Cluster Kit v3. Clustered v3 flow cells 
are loaded onto HiSeq 2000 instruments and sequenced on 100 bp paired-end, non-indexed 
runs. All samples are sequenced on independent lanes. Sequencing runs are performed based 
on the HiSeq 2000 User Guide, using Illumina TruSeq SBS v3 Reagents. Illumina HiSeq 
Control Software (HCS) and Real-Time Analysis (RTA) used on HiSeq 2000 sequencing 
runs for real-time image analysis and base calling. 
RNA extraction 
P33 cells were detached using Trypsin (Cat. #25300, Gibco) and after centrifugation, the cell 
pellet was lysed in QIAzol buffer and frozen at −80°C. The cell pellet in QIAzol was thawed. 
Chloroform was added and the sample was centrifuged at 12000 g for 15 min at 4°C. The 
upper aqueous layer was removed and 1.5 times the volume of the aqueous layer of ethanol 
was added. RNA in the aqueous layer was bound to an RNeasy Mini column by loading the 
aqueous layer + ethanol to the top of the column and spinning at 8000 g for 15 s at room 
temperature. The column was washed once with Buffer RWT, then twice with Buffer RPE. 
RNA was eluted from the column with 2 washes of 30 µL of water. 
Strand-specific RNA-Seq library preparation 
PolyA RNA was isolated from 500 ng of input RNA using oligo(dT)25 Dynabeads 
(Invitrogen) by binding the RNA to the Dynabeads, collecting the beads with a magnetic 
rack, and removing the supernatant containing non-polyA RNA. The Dynabeads were 
washed in washing buffer then the mRNA was eluted in TE buffer. The binding and washing 
steps were repeated to remove remaining non-polyA RNA. After the binding and washing, 
the Dynabeads were resuspended in 2× Superscript III first-strand buffer with 10 mM DTT 
and incubated at 94°C for 6 min to fragment the mRNA then immediately cooled on ice. The 
Dynabeads were collected on a magnetic stand and the fragment mRNA was moved to a new 
tube. 
Fragmented mRNA in 2× RT buffer, random hexamers, and RNasin Plus was heated at 50°C 
for 1 min to denature the RNA then placed immediately on ice. To this, water, Actinomycin 
D, DTT, dNTPs, and SuperScript III (Invitrogen) were added and reverse transcription was 
performed by incubating the mixture at 25°C for 10 min then at 50°C for 50 min. RNAClean 
XP beads (Agencourt) were added to the mixture and incubated on ice for 15 min. The beads 
were collected on a magnetic stand, washed twice with 75% ethanol then air-dried for 5 min. 
The RNA/cDNA hybrid was eluted in water. 
A second strand reaction master mix including either 10× Blue Buffer or NEBuffer 2, dNTP 
(with dATP, dCTP, dGTP, and dUTP), RNase H, DNA polymerase I (Enzymatics), and 
water was added to each sample and incubated at 16°C for 2.5 h. Double-stranded DNA was 
purified using 1.8 volumes of AMPure XP beads (Agencourt) and eluted in water. 
The DNA was dA-tailed by adding either 10× Blue Buffer or NEBuffer 2, dATP, water, and 
Klenow 3′-5′ exo (Enzymatics) and incubated at 37°C for 30 min. The dsDNA was purified 
using AMPure XP beads, and eluted in water. To each sample, a specific barcode adapter was 
added, along with Rapid Ligation Buffer and T4 DNA Ligase HC (Enzymatics). The Y-shape 
adapter ligation was performed by incubating at room temperature for 15 min. 
DNA was purified and size selected by cleaning up with AMPure XP beads 3 consecutive 
times and eluting in TE buffer. The first cleanup was performed with 1 volume of AMPure 
XP beads, the second with 1.4 volumes, and the last with 1 volume incubated at room 
temperature for 5 min without washing to perform size selection. The supernatant was 
transferred to a tube with half of the new volume of AMPure XP beads and incubated at room 
temperature for 15 min. The beads were collected on a magnetic stand and washed twice with 
75% ethanol. The DNA was eluted in water. 
The second strand of DNA was digested with Uracil DNA Glycosylase (Enzymatics) at 37°C 
for 15 min. The PCR reaction was set up containing UDG-digested DNA, primer A and B, 
Phusion HF Buffer, dNTP, water, and Phusion II (New England Biolabs). The reaction was 
incubated at 94°C for 2 min, followed by 10–12 cycles of amplification (98°C for 10 s, 65°C 
for 30 s, 72°C for 30 s). The DNA libraries were purified with 1.4 volumes of AMPure XP 
beads and eluted in TE buffer. 
Proteomics library preparation 
P33 cells were washed twice with DBPS and covered with a 1× complete protease inhibitor 
cocktail diluted in ddH2O and frozen at −80°C. Refer to Additional file 8 for complete details 
on the proteomic sample preparation and liquid chromatography – mass spectrometry (LC-
MS/MS) analysis. 
Whole genome sequencing 
SH-SY5Y paired-end whole genome sequencing was done at Illumina and Complete 
Genomics (CG), Inc (Mountain View, CA) (CG). Whole-genome sequencing was performed 
(CG) using their proprietary sequencing-by-ligation technology [10]. CG performed primary 
data analysis using CGAtools v2.0.2.10 including image analysis, base calling, alignment and 
variant calling. Illumina primary data analysis was performed using CASAVA pipeline v1.8. 
For both sequencings reads were mapped against the human reference genome (hg19, NCBI 
build 37). 
For CG data, coverage statistics were derived from coverage and coverageRefScore files for 
each chromosome. Coverage at every base was assessed directly from these files. The depth 
of coverage roughly follows a normal distribution with significant low and high tails, and has 
very high sequence-specific local fluctuation. This fluctuation mainly relates to G + C content 
and is consistent among genomes analyzed with similar versions of CGAtools. We corrected 
the sequencing coverage observed in CG data by comparing to the coverage observed in 590 
genomes available internally at the Institute for Systems Biology, produced with comparable 
versions of the same technology. To do this, we computed the average coverage level in each 
1 kb bin in the 590 reference genomes, after scaling each genome to the geometric average of 
total autosomal coverage, stratified by G + C content. We then normalised the coverage 
levels in each 1 kb window of SH-SY5Y to the corresponding median value observed in the 
reference genome set. For Illumina, coverage information was extracted directly from BAM 
(binary sequence alignment format) files. To compare CNVs detected with results in 
literature, CNV measurements of SH-SY5Y using CGH arrays [36] were converted from 
hg17 to hg19 coordinates (Additional file 3) using the LiftOver tool [62]. 
For CG, SNVs were derived from the var file. For Illumina, SNVs were extracted from 
CASAVA output files. SNVs from both platforms were combined into CG testvariant format 
and compared using custom perl/python scripts. ANNOVAR [21] was used to annotate the 
SNVs with gene annotations downloaded from the UCSC browser [23] 
(http://www.genome.ucsc.edu/). 
Small insertions and deletions were derived for CG from the VAR file. Indels for Illumina 
were obtained from CASAVA output files. Copy number variation (CNV) events were taken 
from cnvSegmentsNondiploidBeta-* file and high-confidence structural variation (SV) events 
were taken from /highConfidenceSvEventsBeta-* file. The mobile element insertion (MEI) 
regions were found from mobileElementInsertionsBeta-* file. 
Transcriptome analysis 
RNA-Seq FASTQ files were quality trimmed using the novoalign 
(http://www.novocraft.com) tool with the –a parameter. Sequencing reads were aligned to the 
UCSC Homo sapiens reference genome hg19 using TopHat v2.0.8 [63,64], which is 
integrated with Bowtie v2.0.5 [65] as mapping tool. TopHat removes a small number of reads 
based on read quality and then maps the reads to a provided reference genome sequence. The 
pre-built UCSC H. sapiens hg19 bowtie2 index as well as the Ensembl GRCg37 were 
downloaded from the TopHat Illumina iGenomes site 
(http://tophat.cbcb.umd.edu/igenomes.html). TopHat were run with default settings: maximal 
40 alignments per read were allowed, with up to 2 mismatches per alignment. Additionally, 
the flags ‘no-novel-juncs’ with library-type ‘fr-firststrand’ were used to suppress the 
prediction of new junction sites and to ensure stranded alignments, respectively. The resulting 
aligned reads in BAM format were analysed further by Cufflinks v2.0.2 [64] in several ways. 
Cufflinks assembled the aligned reads into transcripts using the Ensembl gene annotation and 
reported the expression of those transcripts in Fragments Per Kilobase of exon per Million 
fragments mapped (FPKM). FPKM is an expression of the relative abundance of transcripts. 
Small variants (SNPs and indels) were called using SAMtools [38] and BEDtools [66]. Using 
the BAM file generated with TopHat samtools mpileup (−u –q10), bcftools (view –g) and 
vcfutils.pl (varFilter) from the SAMtools software suite as well as awk (‘($6 > = 50)’) is used 
to produce a VCF (Variant Call Format) file filtered for minimum quality score of 50. The 
resulting VCF file is further filtered for falsely called SNPs near splice sites using the 
BEDtools package to filter out SNPs within a 5 nt window around known splice site 
junctions. 
Proteomics analysis 
A FASTA protein sequence database was created by combining two FASTA databases – (i) 
protein sequences from the human genome reference hg19 and (ii) protein sequences 
modified by genomic variants - SNVs, short indels and block substitutions. To merge the two 
FASTA files, both have been concatenated and redundance has been reduced by cd-hit 
(parameters: −c 1 –I 0 –G 1 –p 1 –I 6 –d 200 –S 0 –M 16000). If a protein sequence occurred 
repeatedly, their names were grouped and assigned with a “#” symbol as separator. This 
approach allowed to track if an identified protein by MaxQuant [67] is solely based on the 
additional genomic information. 
Secondly, the acquired LC-ESI MS/MS data were searched with MaxQuant (v. 1.3.0.5) 
against the combined FASTA protein database. Default parameters on MaxQuant for 
unlabelled data were used. Oxidation (M) and N-acetylating have been considered as variable 
modifications as well as carbamidomethylation on cysteine as a fixed modification. Two 
missed cleavage sites (Trypsin/P) were allowed and a mass tolerance of 20 ppm of HCD 
spectra as well as 0.5 Da for CID spectra has been allowed. MS1 precursor mass tolerance 
was also left at 20 ppm for the first search and 6 ppm for the main search. 
The iBAQ [43] method has been used to roughly estimate the absolute quantities of the 
identified proteins. Since we did not use any spike-in, iBAQ was run without the “log fit” 
option and the resulting values will just reflect the ordering of the amounts of (and the 
relative difference between two different proteins in the same run) rather than the absolute 
quantities in an analytical meaning. 
Diseases related to SH-SY5Y using text mining 
The goal of literature analysis was to identify diseases that have been studied using the cell 
line and or its derivatives. For the purpose of corpus construction we first searched the 
PubMed collection of abstracts from MEDLINE (http://www.ncbi.nlm.nih.gov/pubmed), 
PubMed Central (PMC), which is a free full-text archive of biomedical and life sciences 
journals (http://www.ncbi.nlm.nih.gov/pmc/), and Elsevier repository for articles that 
mentioned SH-SY5Y cell line (case and dash insensitive) or its spelling variations (e.g., “sh-
sy5y cells”) Next, we selected the publications that mentioned the cell line in the title, 
abstract, list of keywords, section headings, or table/figure captions. These are cues that help 
to identify principle aspects of article’s content [68,69]. We executed the above searches with 
Biopython tools [70] which allowed accessing and querying of PubMed repository, and PMC 
online facilities to search through the PMC collection. In addition, we implemented a full text 
parser of the Elsevier articles using the lxml.etree library [71]. 
After removal of duplicates, items without either title or authors, and items with less than six 
full sentences (an approximate length of title and abstract), we obtained a collection of 5,353 
abstracts and full text articles that dealt with SH-SY5Y cell line. We used Reflect annotation 
software [72] to identify disease names in the text. Applying heuristic rules described above, 
we labelled articles with the corresponding disease name, and ranked diseases by their 
collection frequency. 
Generation of disease networks 
Our approach to the cell line evaluation as in vitro model relies on the understanding of 
diseases as genetic network perturbations [73,74], which requires considering not only single 
genes of interest but also their role in a complex pathogenic process. For this reason, we 
represent diseases and process of interest as networks in which nodes are genes (or proteins) 
and edges are protein-protein interactions. Note that when we scored SH-SY5Y with regard 
to the Parkinson’s disease modules, we extracted relevant sub-networks directly from the PD 
map. Alternatively, disease-related networks were built using Online Mendelian Inheritance 
in Man (OMIM) [75]– a catalogue of human genes and genetic disorders; and STRING – a 
state-of-the-art database of known and predicted protein-protein interactions [76] version 9.0, 
from which we extracted human-related undirected network with 18600 nodes and 1640707 
edges. In the experiments described here we considered interactions of all types, provided 
their confidence score was > = 0.7, classified as “high” by the database authors. (See [44] for 
more details about interactions in STRING.) This reduced the network size to 14688 nodes 
and 170570 edges. The procedure of disease-related network construction consists of 
selecting genes described in OMIM as having mutations with causative effect on the disorder; 
mapping them on the human network, derived from STRING; forming the final network by 
expanding the core genes with their neighbours at distance one. The choice of the expansion 
radius is explained by the high average node degree (23.22) of our background STRING–
derived network. See Additional file 9 for the list of genes in the network constructed for 
each disease and module and the list of genes taken as damaged in SH-SY5Y. 
Description of the cell line suitability scoring: BC-ratio 
Perturbations applied to the networks affected by the genes mutated in the cell line may 
produce different phenotypic outputs than the same perturbations applied to the intact 
networks. Therefore we evaluated the adequacy of the cell line by estimating the impact of 
the mutated genes on the network that represented the process under study. This analysis 
aims to first evaluate the node’s importance in the network, and next extend the node-wise 
information to the entire cell line. 
Node’s importance is related to positional advantage it has in the network, and is expressed in 
terms of “centrality”. Different centrality types reflect different positional properties of a 
node. Node degree is associated with the node’s visibility and its ability to directly 
communicate with the other nodes [47]. It does not consider indirect connections of a node 
and therefore can be considered as the measure of its local importance. Closeness is the 
reciprocal of mean shortest-path distance between a node and all other nodes that can be 
reached from it. It is interpreted in terms of how fast a node can communicate with the others 
[77]. Betweenness centrality measures the extent to which a vertex lies on the paths between 
the others and, as a consequence, the extent to which the node influences the information 
flow in the network [78]. In yet another view, node’s centrality is a function of centrality of 
its neighbours [79] so called power centrality. It is close to eigenvector centrality, which is 
seen as an attempt to identify important nodes with regard to the overall or global structure of 
the network. Among this wide variety of centrality metrics we choose betweenness centrality 
for its emphasis of the nodes ability to alter the information flow in a network. 
Betweenness centrality of a node expresses how much information flows through that node. 
Betweenness centrality g of node v in the network G is given by Equation 1, 
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where σst is the total number of shortest paths between the nodes s, t ∈ G, and σst(v) is the 
number of shortest path that go through v. 
In order to quantitatively assess the cell line suitability, we extended the metric from 
individual node characteristic to the characteristic of node types. First of all we mapped the 
genes mutated in the cell line onto the network under study and labelled all the nodes as 
“Damaged” or “Intact”. A gene was labelled as “damaged” if it contained a rare non-
synonymous or splice-site SNV, indel or block substitution or if it was found inside a region 
affected by a CNV or a rare SV. A rare SNV, indel or block substitution occurred with less 
than 5% frequency in 1000 Genomes Project, 6500 Exome Sequencing Project and Complete 
Genomics 69 Baseline Genomes dataset. A rare SV was one that was never found in the 
Complete Genomics Baseline Genome dataset. Next we tried to assess the impact of the 
damaged nodes on the network. We achieved this by comparing the overall betweenness 
centrality scores of the damaged and intact nodes. We called this metric BC-ratio µ, which 
was formally defined as follows: 
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The value of µ is in range [0:1]. The higher is the BC-ratio value the more is the impact of 
nodes corresponding to the genes mutated in the cell line on the information flow in the 
network. The PBC values indicate the probability that the calculated BC-ratio resulted from a 
random distribution of mutated genes in the network. 
To test the metric we generated, for each disease and process, 1000 alternative networks for 
which we preserved the original topology and counts of damaged/intact nodes but 
randomized label assignments. We scored each randomized network and calculated pBC-value 
– the probability of obtaining higher BC-ratio with the randomized networks than the one we 
have obtained with the actual data. PBC-value > 0.05 indicates that nodes with high 
betweenness-centrality in the disease/process network do not significantly correlate with the 
genes mutated in the cell line –null hypothesis. On the contrary, pBC-value < 0.05 indicates 
that nodes with high betweenness-centrality in the disease network do significantly correlate 
with the genes mutated in the cell line – alternative hypothesis. Validity of the null hypothesis 
gives us more ground to assume that from the genetic perspective the cell line is an 
acceptable candidate for modelling of the disease or process. Based on the pBC-values for 
various diseases and processes (Table 2, Table 3), we cannot confidently reject the null 
hypotheses for all but two diseases, which are neuroblastoma and Alzheimer’s disease. 
In addition to the BC-ratio which is based on the betweenness centrality of the nodes, we 
calculated the SH-SY5Y integrity with the diseases and process in question using degree, 
closeness and flow (also known as “random walk”) betweenness centralities [78,80]. The 
difference between the latter and the betweenness centrality we have been using so far is that 
it considers contributions from all paths in the network, not only the shortest, although the 
latter still counts for more. It has been shown that protein-protein interaction networks can 
efficiently be modelled with the random walk betweenness centrality [81] so we were 
interested to compare the two measures in our experimental setting. Alternative cell line 
scoring implied substitution of the shortest path betweenness centrality of the nodes with one 
of the selected centrality types. Otherwise the procedure remained the same as specified in 
Equation 2. 
Results of the cell line suitability computations using various centrality metrics are given in 
Tables 2 and 3. Instead of comparing the cell line scoring values directly we compare 
centrality values of the individual nodes given by the various metrics. We believe that this 
information lets us get more insight into the agreement between the centrality types. Table 5 
shows correlation between the centrality metrics averaged across diseases and processes. 
Betweenness only moderately correlated with the degree (0.593) and less so with closeness 
centrality (0.463) while flow betweenness showed relatively high agreement with the degree 
(0.7). Degree and closeness showed higher intercorrelation than with the betweenness 
(0.622). Among all metrics, betweenness and flow betweenness centralities showed the 
highest correlation (0.955). It suggests that in our experiments either metric could have been 
used for the cell line suitability evaluation. However the absolute values of the cell line 
suitability would have not been identical (see Tables 2 and 3, columns “BC-ratio” and “Flow 
BC”) due to the ability of the flow betweenness centrality to highlight nodes which, although 
not lying on the shortest paths or occurring on more than one of them (hence, having shortest 
path betweenness centrality equal or close to 0.0), still contribute to the information flow. 
Table 6 shows gene ranking in the Mitochondria module of the Parkinson’s disease map in 
various centrality measures. It can be seen that gene’s rank in both betweenness metrics are 
very close or even identical while much less so with respect to the degree and closeness 
centrality. Ranking of PARK2 and PINK1 tells us that nodes which do not have high degree 
or closeness may still play an important role in information flow in the network. 
Alternatively, positions of PDHA1 and to some less extent that of DLD suggest that having 
high degree and closeness does not necessarily mean to be a broker. Yet, in some other cases 
all centrality metrics may agree on the node’s importance as can be seen on SNCA and CYCS. 
Overall we would conclude that various metrics should not be regarded as mutually 
exchangeable. Rather one could choose the metric taking into account the positional 
advantage it emphasizes. Our approach to the cell line scoring was motivated by the 
assumption that changes in one gene may affect the entire disease or process network. To 
model this phenomenon, we were looking for a measure that would reflect node’s role in 
information transmission over the network. This is the reason why we choose betweenness 
centrality. 
Table 5 Correlation between various centrality metrics 
 Centrality 
Degree Closeness Betweenness Flow betweenness 
Degree  0.622 0.593 0.700 
Closeness   0.463 0.592 
Betweenness    0.969 
Flow betweenness     
The correlation between the different measures of node centrality was calculated for each 
network. The correlation scores were then averaged over all the networks corresponding to 
the different diseases and PD modules. 
Table 6 Gene scoring agreement across various centrality metrics 
Gene name Rank according to a centrality metric 
Degree Closeness Betweenness Flow betweenness 
PARK2 24 17 1 1 
SNCA 4 4 2 3 
PINK1 25 32 3 2 
CYCS 3 3 4 4 
DLD 1 1 5 5 
VDAC1 32 12 6 6 
PDHA1 2 2 7 8 
SLC25A4 18 5 8 7 
BCL2 43 50 9 9 
BECN1 42 64 10 13 
We show top ten genes from the Mitochondria module of the Parkinson’s. 
Disease map, ordered according to the Betweenness centrality rank. 
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